Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments -
omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in
inner-city children and adolescents with allergic persistent asthma when initiated
approximately 4 -6 weeks prior to the start of the first day of each participant's school
year.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)